In young adults, about half of the cold-related reduction in skin blood flow during cold exposure is mediated by noradrenaline, while the remainder is attributable to other substances co-released with noradrenaline that have yet to be identified. r What is the main finding and its importance?
Introduction
Blood flow to human skin varies widely based on environmental conditions, ranging from nearly zero during cold exposure to ß8 l min −1 during passive heating (Rowell, 1983; Johnson et al. 2014 ). This wide range of blood flow is ultimately controlled by dual sympathetic innervation, where adrenergic axons mediate vasoconstriction (VC) and sympathetic cholinergic axons mediate active vasodilatation (VD; Johnson et al. 2014) . However, noradrenaline (NA) and acetylcholine release explain only about half of this vasomotor range, thereby leaving a large component of the vasomotor response attributable to cotransmitter-mediated mechanisms (Kellogg et al. 1989 (Kellogg et al. , 1995 Stephens et al. 2001) . At thermoneutral or cooler ambient temperatures, skin blood flow is controlled by tonic adrenergic stimulation, which is evidenced by prejunctional blockade of neurotransmitter release or surgical sympathectomy resulting in complete abolition of the reflex VC response (Goldstein et al. 1986; Kellogg et al. 1989 ; Thompson & Kenney, 2004) . Postjunctional adrenoreceptor blockade inhibits only ß60% of the reflex VC response to cold exposure in young adults (Stephens et al. 2001; Thompson & Kenney, 2004; Lang et al. 2009) , and thus the remaining 40% is attributable to other neurotransmitters co-released with NA. Although there are conflicting data implicating neuropeptide Y (NPY) as a cotransmitter in human skin (Stephens et al. 2004; Thompson, 2005; Simmons et al. 2011) , the identity of the cotransmitter(s) remains unknown.
Based primarily on animal and in vitro human studies, both NPY and ATP have emerged as the most likely cotransmitter substances released from perivascular adrenergic nerve terminals (Hodges et al. 2009; Burnstock et al. 2012) . Both are co-released with NA but in different vesicular populations and at different stimulation frequencies Bradley et al. 2003) . Neuropeptide Y, released from large dense core vesicles at higher sympathetic stimulation frequencies, binds to postjunctional Y 1 receptors to evoke VC (Ekblad et al. 1984; Morris, 1994; Lundberg & Modin, 1995; Nilsson et al. 1996; Racchi et al. 1997; Han et al. 1998; Heath, 1998; Chu et al. 2003) . ATP, released from smaller synaptic vesicles at lower stimulation frequencies, acts on postjunctional P 2X receptors to evoke VC (Flavahan & Vanhoutte, 1986; Taddei et al. 1990; Racchi et al. 1999; Koganezawa et al. 2006; Burnstock, 2007) . In vivo work in humans revealed that intradermal infusion of the NPY Y 1 antagonist, BIBP-3226, blunted the reflex VC response to cooling (Stephens et al. 2001 (Stephens et al. , 2004 ; however, this was not consistently observed when using the same drug antagonist during cooling (Thompson, 2005; Greaney et al. 2015a) or hypoxic conditions (Simmons et al. 2011) .
No similar studies have been performed in human skin to investigate the role of ATP.
Although it has recently been demonstrated that ATP has a dilatory influence in skin (Fujii et al. 2015a,b) , the purpose of this study was to determine whether ATP serves as a cotransmitter that contributes to the VC response during cold exposure. Thus, we hypothesize that the reflex cutaneous VC response during whole-body cooling will be attenuated by infusion of suramin, a P 2X receptor antagonist. We further hypothesize that combined purinergic and adrenergic blockade will additively reduce the VC response, thereby explaining part of the cotransmitter-mediated VC response.
Methods

Subjects
All experimental procedures were approved by the Des Moines University Institutional Review Board (approval no. 03-14-02) and followed the standards set by the Declaration of Helsinki. After providing voluntary verbal and written informed consent, 10 healthy, young subjects (25 ± 2 years; five men and five women) participated in the study [body mass index 22 ± 3 kg m −2 ; resting mean arterial pressure (MAP) 79 ± 5 mmHg; fasting blood glucose 89 ± 6 mg dl −1 ; total cholesterol 163 ± 24 mg dl −1 ; and low-density lipoprotein cholesterol 95 ± 19 mg dl −1 ]. Subjects were not using tobacco products nor were they taking prescription medications (e.g. antidepressants, anxiolytics) that would otherwise affect thermoregulatory or vascular function. Young women were tested during the low hormone phase (days 2-7) of the menstrual cycle or during the placebo week of oral contraceptives (Charkoudian & Johnson, 1999) . On the days of the experiment, subjects arrived at the laboratory after abstention from alcohol and caffeine (>12 h) as well as strenuous physical activity or vitamin supplemention (>24 h).
Instrumentation
Subjects reported to the laboratory (room temperature 23°C) in the morning (08.00-13.00 h) and were positioned in a semi-recumbent position during both experimental visits. Three microdialysis (MD) probes (10 mm, 30 kDa molecular mass cut-off membrane, MD 2000; Bioanalytical Systems, West Lafayette, IN, USA) were aseptically placed into the dermis of the ventral forearm for the perfusion of drug agonists or antagonists in a process explained previously (FDA IND# 122309; Lang & Kolb, 2015) . All drugs were weighed in the laboratory (Mettler-Toledo MS105, Columbus, OH, USA), mixed in lactated Ringer solution, and filtered using syringe To reduce skin temperature (T sk ), subjects wore a water-perfusion suit that covered the entire body except the face, feet, hands and instrumented forearm. The unweighted T sk was collected from six copper-constantan thermocouples taped to the skin of the chest, thigh, back, calf, abdomen and arm. To ensure that any vasomotor changes during cooling were reflex in origin, local skin temperature at each MD site was held constant at 33°C using a heater (moorVMS-HEAT; Moor Instruments, Axminster, UK) attached to the skin surface.
Red blood cell flux [laser Doppler Flux (LDF)], an index of skin blood flow, was continuously measured by multifibre integrated laser Doppler probes (moorVMS-LDF; Moor Instruments) positioned within local heaters on the skin surface. Arterial blood pressure was measured on the contralateral arm using an automated cuff (Suntech Tango M2, Morrisville, NC, USA) every 5 min. Mean arterial pressure (MAP) was calculated as the diastolic blood pressure plus one-third of the pulse pressure. Heart rate was monitored using a lead II electrocardiogram (CT-1000 cardiotachometer; CWE Inc., Ardmore, PA, USA). Cutaneous vascular conductance (CVC) was calculated as the ratio of LDF to MAP and expressed as a percentage change from baseline (% CVC BASELINE ).
Protocol 1: first experimental visit
After instrumentation, MD probe sites were randomly assigned for continuous perfusion of the following solutions: (i) lactated Ringer solution (control); (ii) 10 mM L-NAME, a competitive nitric oxide synthase (NOS) inhibitor; and (iii) 10 mM L-NAME plus 1 mM suramin, a non-selective purinergic receptor antagonist. Drug dosing was determined by prior MD studies (Stephens et al. 2001; Thompson & Kenney, 2004; Lang et al. 2009 ) and by pilot protocols testing increasing doses of ATP on the VC response in L-NAME-pretreated sites. Doses were selected based on the maximal VC response elicited by ATP that could subsequently be blocked by suramin. After needle insertion hyperaemia resolved, 0.66 mM ATP was added to drug perfusates at each MD site for 10 min. After a 30 min washout with the assigned drug to re-establish baseline, reflex cutaneous VC was elicited by circulating cold water through the suit to reduce T sk gradually from 34.0 to 30.5°C over a 30 min period and maintain it at 30.5°C for an additional 10 min. Rewarming for ß30 min followed to return T sk to 34.0°C. After achievement of normothermia, 1 mM tyramine was administered for 10 min at each MD site to induce localized endogenous adrenergic neurotransmitter release pharmacologically. Vascular responsivity was then tested by briefly increasing the local heaters to 42°C at each site until an increase in LDF was observed (ß3 min).
Protocol 2: second experimental visit
Approximately a week later, participants returned to complete a second MD experiment. After instrumentation, MD probe sites were randomly assigned for continuous perfusion of the following solutions: (i) lactated Ringer solution (control); (ii) 10 mM L-NAME plus 1 mM suramin; and (iii) 10 mM L-NAME plus 1 mM suramin plus adrenoreceptor blockade with 5 mM yohimbine plus 1 mM propranolol. Exactly the same as the first visit, a 10 min perfusion of 0.66 mM ATP was performed to verify the efficacy of the suramin block followed by the 40 min gradual whole-body cooling protocol. After rewarming, 1 × 10 −6 mM NA was administered for 10 min at each MD site to test the efficacy of adrenoreceptor blockade. Then, vascular responsivity was tested by local warming of skin to 42°C.
Data acquisition and analysis
Data were collected at 1000 Hz and stored for offline analysis (LabChart v7.0 and PowerLab 16/35; ADInstruments, Bella Vista, NSW, Australia). The LDF data were processed into 1 s averages every fourth second throughout the protocol. Cutaneous vascular conductance was calculated toward the end of each drug perfusion period and for every 0.5°C drop in T sk during cooling. A two-way repeated-measures ANOVA followed by Bonferroni post hoc analysis was conducted (SPSS version 22; SPSS, Chicago, IL, USA) to detect drug treatment effects at different time points in the protocol. Statistical significance was set at α = 0.05. An a priori sample size analysis was performed, which indicated that 10 participants were needed to detect significant differences at P < 0.05 and 80% power. All data are represented as means ± SD.
Results
The absolute CVC values (calculated as laser Doppler flux per millimetre of mercury) at each MD probe site during various time points within protocol 1 and protocol 2 are represented in Table 1 . For protocol 1, CVC values were generally lower, although not significant, in the L-NAME-treated sites. The exception to this was during tyramine perfusion, when L-NAME differed from Absolute cutaneous vascular conductance values (laser Doppler flux per millimetre of mercury) in young subjects (n = 10) at baseline, during exogenous ATP perfusion, after ATP washout, during maximal cooling (i.e. mean skin temperature = 30.5°C), after rewarming and during tyramine (protocol 1) or noradrenaline infusion (protocol 2). Abbreviations: L, L-NAME; P, propranolol; S, suramin; and Y, yohimbine. * P < 0.05 versus control site. † P < 0.05 versus preceding time point (i.e. baseline, washout or rewarm).
the control site (P < 0.05). ATP elicited a decreased CVC from baseline at the L-NAME site (P < 0.05) but this was not observed at the other sites. Cooling and tyramine reduced CVC at all sites relative to the preceding washout or rewarming period, respectively (P < 0.05). The only potential exception was cooling at the control site (P = 0.065). For protocol 2, ATP evoked a reduced CVC from baseline at the control site (P = 0.049). Cooling reduced CVC at all sites relative to the preceding washout period (P < 0.05), and exogenous NA reduced CVC relative to the preceding rewarming period only at the suramin plus L-NAME site (P < 0.05).
The VC response to a localized 0.66 mM dose of ATP is illustrated in Fig. 1 . For protocol 1 (Fig. 1A) , ATP perfusion elicited a greater VC response in the L-NAME-treated site (−21 ± 2 % CVC BASELINE ) compared with the control site (P < 0.05), and this was abolished when L-NAME was perfused in combination with the non-selective purinergic receptor antagonist suramin. Likewise, in protocol 2 (Fig. 1B) , ATP-mediated VC was completely abolished at the sites treated with suramin. Compared with the suramin-treated sites, the control site exhibited greater VC during ATP perfusion (P < 0.05).
The reflex VC response was represented as the percentage change in CVC from baseline for every 0.5°C drop in T sk during whole-body cooling (Fig. 2) . For protocol 1 (Fig. 2A) , the control and L-NAME sites showed similar deviations from baseline with cooling. However, the combination L-NAME and suramin site exhibited a reduced VC response to cooling (T sk ࣘ 32°C; P < 0.05 except at T sk = 31.0°C). Likewise, during protocol 2, the VC response at the L-NAME plus suramin site was blunted with respect to the control site (T sk ࣘ 33.5°C; P < 0.05). Combined purinergic and adrenoreceptor antagonism (L-NAME plus suramin plus yohimbine plus propranolol site) additively attenuated the VC response compared with the control (T sk ࣘ 33.5°C; P < 0.05) and L-NAME plus suramin sites (T sk ࣘ 32.5°C; P < 0.05). Compared with the control site (−39 ± 3 % CVC BASELINE ), the peak VC response to whole-body cooling was blunted with purinergic blockade (−21 ± 2 % CVC BASELINE ) and further attenuated in the combined purinergic and adrenoreceptor blocked site (−9 ± 1 % CVC BASELINE ).
During protocol 1, the peak VC response pharmacologically induced by the administration of 1 mM tyramine was compared across MD sites (Fig. 3) . The VC response was similar between control and L-NAME sites. However, compared with the control and L-NAME sites, the addition of suramin (L + S site) attenuated the VC response (P < 0.05).
During protocol 2, the peak VC response elicited by intradermal perfusion of 1 × 10 −6 M NA was compared across MD sites (Fig. 4) . Both the control and L-NAME plus suramin sites experienced similar responses to NA. Addition of the NA receptor antagonists, yohimbine and propranolol, completely blocked the VC response to NA (P < 0.05).
Discussion
The primary finding from this study was that, using an in vivo methodological approach, endogenous ATP directly contributes to the reflex cutaneous VC response in humans. This was evidenced by the discovery that purinergic antagonism with suramin inhibited cutaneous VC induced pharmacologically with tyramine or by whole-body cooling. Further inhibition was observed with combined purinergic and adrenoreceptor blockade during whole-body cooling, leaving ß20% of the total reflex VC response that was not explained by ATP and NA antagonism. Additionally, exogenous ATP in the presence of L-NAME unmasked a vasoconstriction response that was blocked with suramin. Collectively, these data indicate that ATP has a vasoconstrictor role in skin, potentially as a sympathetic cotransmitter, which is important to full expression of the reflex VC response to cold exposure in healthy young adults.
J. A. Lang and others
It is well established that ATP serves as a vital intracellular energy source; however, it is increasingly apparent that ATP has an important extracellular role in modulating vasomotor function by acting on P 2 receptors located on the endothelium and vascular smooth muscle (Burnstock, 2007 (Burnstock, , 2008 . Although several P 2 receptor subtypes have been identified, this receptor class is divided into P 2X ligand-gated ion channels and P 2Y G-protein-coupled receptor families (Burnstock & Kennedy, 1985; Burnstock, 2012 Burnstock, , 2012 . Intravascular sources of ATP, such as that released from endothelial cells or offloaded from red blood cells, elicit vasodilatation by acting on P 2 receptors located on the endothelium to increase vasoactive factors, such as nitric oxide (Duff et al. 1954; Rongen et al. 1994; Wingo et al. 2010; Fujii et al. 2015b) . However, ATP co-released from perivascular axon terminals binds to P 2X receptors to increase the intracellular calcium concentration and contract vascular smooth muscle (Burnstock, 1988 (Burnstock, , 2008 . In the present study, the VC influence of ATP was unmasked by adding L-NAME to the perfusate (Fig. 1A) . Inhibiting the endothelial component of ATP allowed for the examination of the VC mediated principally by ATP released from perivascular nerve terminals.
ATP cotransmission has been demonstrated in multiple vascular beds across various animal and in vitro human tissue models (Flavahan & Vanhoutte, 1986; Taddei et al. 1990; Racchi et al. 1999; Koganezawa et al. 2006 ; ATP elicited vasoconstriction at L-NAME-pretreated sites, which was blocked with suramin, a purinergic receptor antagonist. Abbreviations: L, L-NAME; P, propranolol; S, suramin; and Y, yohimbine. * P < 0.05 versus control site. + P < 0.05 versus L-NAME site. Burnstock, 2007 Burnstock, , 2012 . ATP is co-stored with NA in smaller synaptic vesicles within sympathetic axon nerve terminals in an estimated molar ratio ranging between 7:1 and 12:1 NA:ATP (Burnstock, 2007) . Upon vesicular release with NA, ATP binds to P 2X receptors to elicit VC. The relative contribution of ATP varies depending on the vascular bed and species. In human skin, our data indicate that ATP contributes ß40% of the total VC response. Previous literature in skin has established that this fraction represents the entire cotransmitter-mediated component of reflex VC (Stephens et al. 2001; Thompson & Kenney, 2004; Lang et al. 2009 ). However, our data further indicate that nearly 20% of the reflex VC response remains after combined ATP and NA antagonism. Thus, it is plausible that ATP may be affecting NA release (Li et al. 2005; Koganezawa et al. 2006) or sensitivity of the NA-mediated VC response (Hultstrom et al. 2007) . Further testing would be required to examine the role of ATP in noradrenergic function in skin.
Similar to ATP, there are numerous examples of NPY cotransmission in various tissues (Ekblad et al. 1984; Morris, 1994; Lundberg & Modin, 1995; Nilsson et al. 1996; Racchi et al. 1997; Han et al. 1998; Heath, 1998; Chu et al. 2003) . In contrast to ATP, NPY is co-stored with Purinergic blockade blunted the reflex cutaneous vasoconstriction response. Combined purinergic and adrenoreceptor blockade additively attenuated vasoconstriction to cooling. * P < 0.05 versus control site, + P < 0.05 versus L-NAME site, † P < 0.05 versus L-NAME plus suramin site.
NA in large dense core vesicles and is released at higher sympathetic stimulation frequencies Bradley et al. 2003; Hodges et al. 2009 ). Using similar methodology to the present study, a contributory role for NPY in the reflex cutaneous VC response was discovered by Stephens et al. (2004) , who demonstrated that intradermal microdialysis of a NPY Y 1 antagonist, BIBP-3226, attenuated the reflex VC to whole-body cooling. Moreover, the VC response was nearly abolished with combined NPY and NA antagonism. However, in other studies using the same antagonist during cooling (Thompson, 2005; Greaney et al. 2015a) or hypoxia (Simmons et al. 2011) , there was no observed effect on the cutaneous VC response. One explanation for these apparently contrasting results is that the faster cooling rate used by Stephens et al. (2004) might have increased sympathetic stimulation frequency to a range where more NPY release would have occurred. A slower rate used by Thompson (2005) and in the present study might be insufficient to elicit exocytosis of the large dense core vesicles.
Cutaneous cotransmitter-mediated VC is altered with healthy ageing. It is well established that ß60% of the Noradrenaline-mediated vasoconstriction was unaffected by L-NAME plus suramin treatment but was blunted in the adrenoreceptor inhibited site with yohimbine plus propranolol. * P < 0.05 versus control site. † P < 0.05 versus L-NAME plus suramin site.
total reflex cutaneous VC response in young adults is attributable to NA, while the remaining ß40% is attributable to co-released neurotransmitters (Stephens et al. 2001 (Stephens et al. , 2004 Thompson & Kenney, 2004; Lang et al. 2009 ). In older adults, this cotransmitter component is absent (Thompson & Kenney, 2004; Lang et al. 2009 ). Furthermore, skin sympathetic nerve activity is reduced for a given cooling stimulus (Grassi et al. 2003; Greaney et al. 2015b) . Although further testing would be needed to examine a mechanistic link between nerve activity and cotransmitter release, it is clear from the present study that ATP contributes significantly to the non-adrenergic component of the reflex cutaneous VC response in young healthy adults. Recent work in human skin has revealed that ATP also has a vasodilatory influence. Exogenous intradermal infusion of ATP resulted in a dose-dependent VD that was mediated in part by nitric oxide (Wingo et al. 2010; Fujii et al. 2015b) . However, VD occurred only at higher doses of ATP, which exceeded the concentration used in the present study. Moreover, we found that pretreating a site with an NOS inhibitor resulted in a VC when perfusing an exogenous ATP dose. Endogenously, it is possible that co-released ATP induced by cooling or tyramine causes a VC that is offset by the vasodilatory influence of ATP. This would not have been detected in the present study because the dilatory component was inhibited at both treatment sites. Although this design optimizes the identification of an ATP-mediated VC response, it might not reflect the 'net' effect of co-released ATP. However, this limitation is minimized by the fact that physiological concentrations of ATP are readily catabolized by ectonucleotidases (Zimmermann, 1996) , which suggests that there is less dependence upon interstitial concentration to elicit a vasomotor response (Gifford et al. 2012) . Thus, it appears more likely that the vasomotor effect of ATP depends on the proximity of its source to the receptor target (i.e. adventitial as opposed to endothelial receptors).
Limitations
It is possible that the dilatory component of ATP was not completely blocked by combined L-NAME and suramin perfusion. Fujii et al. (2015b) demonstrated that NOS inhibition, albeit at higher ATP doses, accounted for only part of the VD response. It is possible that other factors, such as endothelium-derived hyperpolarizing factors, might be responsible for ATP-mediated VD that would need to be blocked to isolate fully the VC effect of ATP. However, suramin is a general P 2 receptor antagonist and competitively inhibits both P 2X receptors on vascular smooth muscle and P 2Y receptors on the endothelium (Lambrecht, 1996) . In contrast, identifying the extent to which ATP-mediated VD may offset the endogenous VC response cannot be delineated. The functional assessment of ATP is limited by the pharmacology currently available for human use.
Conclusions
In summary, NOS inhibition unmasked vasoconstriction in response to a 0.66 mM exogenous intradermal dose of ATP, which was subsequently abolished by adding a purinergic receptor inhibitor, suramin, to the perfusate. Suramin also reduced the VC response to whole-body cooling and to tyramine, thereby indicating that ATP makes an important contribution to CVC in young adults. Moreover, combined purinergic and adrenoreceptor blockade further blunted the reflex VC response. Only 20% of the total VC response was not explained by both ATP and NA inhibition. This suggests that ATP acts as a major cotransmitter substance that directly impacts cutaneous vasomotor function.
